AmVac, Ascension GmbH, Helmholtz Center for Infection Research, Max Planck Society deal

AmVac received an exclusive, worldwide license to develop and commercialize vaccines using a modified non-replicating Sendai virus from Max Planck Innovation GmbH, the society's technology transfer agency. Max Planck Innovation will receive an upfront payment and is eligible for milestones and royalties. The society will receive undisclosed equity in AmVac. ...